<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:28:17Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8322456" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8322456</identifier>
        <datestamp>2021-08-06</datestamp>
        <setSpec>neoplasia</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3-mathml3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Neoplasia</journal-id>
              <journal-id journal-id-type="iso-abbrev">Neoplasia</journal-id>
              <journal-title-group>
                <journal-title>Neoplasia (New York, N.Y.)</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1522-8002</issn>
              <issn pub-type="epub">1476-5586</issn>
              <publisher>
                <publisher-name>Neoplasia Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8322456</article-id>
              <article-id pub-id-type="pmcid">PMC8322456</article-id>
              <article-id pub-id-type="pmc-uid">8322456</article-id>
              <article-id pub-id-type="pmid">34298234</article-id>
              <article-id pub-id-type="pii">S1476-5586(21)00054-3</article-id>
              <article-id pub-id-type="doi">10.1016/j.neo.2021.06.013</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" id="au0001">
                  <name>
                    <surname>Brady-Nicholls</surname>
                    <given-names>Renee</given-names>
                  </name>
                  <email>renee.brady@moffitt.org</email>
                  <xref rid="aff0001" ref-type="aff">a</xref>
                  <xref rid="cor0001" ref-type="corresp">⁎</xref>
                </contrib>
                <contrib contrib-type="author" id="au0002">
                  <name>
                    <surname>Zhang</surname>
                    <given-names>Jingsong</given-names>
                  </name>
                  <xref rid="aff0002" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au0003">
                  <name>
                    <surname>Zhang</surname>
                    <given-names>Tian</given-names>
                  </name>
                  <xref rid="aff0003" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author" id="au0004">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Andrew Z.</given-names>
                  </name>
                  <xref rid="aff0004" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author" id="au0005">
                  <name>
                    <surname>Butler</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <xref rid="aff0005" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author" id="au0006">
                  <name>
                    <surname>Gatenby</surname>
                    <given-names>Robert A.</given-names>
                  </name>
                  <xref rid="aff0007" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author" id="au0007">
                  <name>
                    <surname>Enderling</surname>
                    <given-names>Heiko</given-names>
                  </name>
                  <xref rid="aff0001" ref-type="aff">a</xref>
                  <xref rid="aff0002" ref-type="aff">b</xref>
                  <xref rid="aff0007" ref-type="aff">f</xref>
                </contrib>
                <aff id="aff0001"><label>a</label>Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA</aff>
                <aff id="aff0002"><label>b</label>Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA</aff>
                <aff id="aff0003"><label>c</label>Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, 20 Duke Medicine Cir, Durham, NC, USA</aff>
                <aff id="aff0004"><label>d</label>Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA</aff>
                <aff id="aff0005"><label>e</label>Physical Sciences Oncology Center, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, , USA</aff>
                <aff id="aff0007"><label>f</label>Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor0001"><label>⁎</label>Corresponding Author. <email>renee.brady@moffitt.org</email></corresp>
              </author-notes>
              <pub-date pub-type="pmc-release">
                <day>20</day>
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
              <pub-date pub-type="collection">
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <volume>23</volume>
              <issue>9</issue>
              <fpage>851</fpage>
              <lpage>858</lpage>
              <history>
                <date date-type="received">
                  <day>11</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>29</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>29</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 The Authors. Published by Elsevier Inc.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
                </license>
              </permissions>
              <abstract id="abs0001">
                <p>Abiraterone acetate (AA) has been proven effective for metastatic castration-resistant prostate cancer (mCRPC), and it has been proposed that adaptive AA may reduce toxicity and prolong time to progression, when compared to continuous AA. We developed a simple quantitative model of prostate-specific antigen (PSA) dynamics to evaluate prostate cancer (PCa) stem cell enrichment as a plausible driver of AA treatment resistance. The model incorporated PCa stem cells, non-stem PCa cells and PSA dynamics during adaptive therapy. A leave-one-out analysis was used to calibrate and validate the model against longitudinal PSA data from 16 mCRPC patients receiving adaptive AA in a pilot clinical study. Early PSA treatment response dynamics were used to predict patient response to subsequent treatment. We extended the model to incorporate metastatic burden and also investigated the survival benefit of adding concurrent chemotherapy for patients predicted to become resistant. Model simulations demonstrated PCa stem cell self-renewal as a plausible driver of resistance to adaptive therapy. Evolutionary dynamics from individual treatment cycles combined with metastatic burden measurements predicted patient response with 81% accuracy (specificity=92%, sensitivity=50%). In those patients predicted to progress, simulations of the addition of concurrent chemotherapy suggest a benefit between 1% and 11% reduction in probability of progression when compared to adaptive AA alone. This study developed the first mCRPC patient-specific mathematical model to use early PSA treatment response dynamics to predict subsequent responses to adaptive AA, demonstrating the putative value of integrating mathematical modeling into clinical decision making.</p>
              </abstract>
              <kwd-group id="keys0001">
                <title>Keywords</title>
                <kwd>Prostate cancer</kwd>
                <kwd>Metastatic</kwd>
                <kwd>Mathematical</kwd>
                <kwd>Modeling</kwd>
                <kwd>Predictive</kwd>
                <kwd>Adaptive therapy</kwd>
                <kwd>Prostate-specific antigen</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec id="sec0001">
              <title>Introduction</title>
              <p id="para0002">Prostate cancer (PCa) is the most prevalent cancer in men in the US. About 1 in 9 American men will be diagnosed with PCa in his lifetime (&gt;248,000 estimated in 2021) and 1 in 41 will die from it. Consequently, PCa remains the second leading cause of death in American men <xref rid="bib0002" ref-type="bibr">[2]</xref>. Following surgery or radiation treatment, androgen deprivation therapy (ADT) has been the mainstay treatment for hormone sensitive PCa for over 70 years <xref rid="bib0003" ref-type="bibr">[3]</xref>. ADT suppresses the production of testicular androgen, which both the normal and cancerous prostate cells depend on for survival and proliferation <xref rid="bib0004" ref-type="bibr">[4]</xref>. Despite new strategies in “precision medicine” in which the specific therapy is guided by molecular biomarkers for individual patients, treatment protocols are typically based on the conventional strategy of “maximum tolerated dose until progression”. This often results in the competitive release of the resistant phenotype, leading to early treatment progression <xref rid="bib0005" ref-type="bibr">[5]</xref>. In an effort to delay progression, intermittent ADT has been shown to be a promising alternative that reduces toxicity and delays progression <xref rid="bib0006" ref-type="bibr">[6]</xref>, <xref rid="bib0007" ref-type="bibr">[7]</xref>, <xref rid="bib0008" ref-type="bibr">[8]</xref>. Despite this advance, patients inevitably develop castration-resistant prostate cancer, which often progresses to metastatic castration-resistant prostate cancer (mCRPC).</p>
              <p id="para0003">Second-line hormone therapy with abiraterone acetate (AA), which inhibits the production of androgens from other cells by blocking the protein CYP17<sup>9</sup>, has been shown to prolong overall survival when compared to prednisone or placebo <xref rid="bib0009" ref-type="bibr">[9]</xref>, <xref rid="bib0010" ref-type="bibr">[10]</xref>, <xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>. In the COU-AA-302 trial evaluating AA with prednisone versus prednisone alone in mCRPC, AA was shown to improve median overall survival (35.3 with AA vs. 30.1 month without) and more than double median radiographic progression-free survival (16.5 vs. 8.2 months). While radiographic progression-free survival (rPFS) and overall survival (OS) were the primary endpoints, the study also evaluated prostate-specific antigen (PSA) progression. The PSA response rate (PSA decline <inline-formula><mml:math id="M1" altimg="si6.svg"><mml:mo>≥</mml:mo></mml:math></inline-formula> 50%) to AA was 68%, compared to just 29% in the prednisone alone group, with a median time to PSA progression of 11.1 months versus 5.6 months with prednisone alone <xref rid="bib0013" ref-type="bibr">[13]</xref>. It has been proposed that adaptively administering AA in mCRPC, allowing for treatment holidays when a patient has sufficiently responded, may be able to increase overall response and delay progression <xref rid="bib0005" ref-type="bibr">[5]</xref>. However, maximizing the benefit of adaptive therapy requires understanding the dominant drivers of resistance, predicting individual patient responses, and identifying when and how to modulate treatment to maximize response time.</p>
              <p id="para0004">Many mathematical models have been developed to simulate the various biological mechanisms of clinical PCa treatment resistance [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0014" ref-type="bibr">[14]</xref>, <xref rid="bib0015" ref-type="bibr">[15]</xref>, <xref rid="bib0016" ref-type="bibr">[16]</xref>, <xref rid="bib0017" ref-type="bibr">[17]</xref>, <xref rid="bib0018" ref-type="bibr">[18]</xref>, <xref rid="bib0019" ref-type="bibr">[19]</xref>]. These studies have contributed significantly to our understanding of how the different mechanisms that may lead to resistance could be exploited for adaptive therapies, but most mathematical models have yet to be rigorously calibrated and validated with patient-specific disease dynamics, and to be evaluated for predictive power <xref rid="bib0020" ref-type="bibr">[20]</xref>. For predictive certainty, model complexity and uncertainty must be kept proportional to the available data. PSA has been used as a marker of PCa development and progression for many years, despite concerns regarding overdiagnosis and overtreatment. We have previously demonstrated how PSA dynamics, rather than measurements taken at single timepoints, can be used to predict individual patient responses to intermittent hormone therapy in castration-naïve PCa <xref rid="bib0001" ref-type="bibr">[1]</xref>. In more advanced PCa, such as in the case of mCRPC, alternative biomarkers such as cell-free DNA and circulating tumor DNA, have been shown to be correlated with PSA response rates <xref rid="bib0021" ref-type="bibr">[21]</xref>, <xref rid="bib0022" ref-type="bibr">[22]</xref>, <xref rid="bib0023" ref-type="bibr">[23]</xref>, <xref rid="bib0024" ref-type="bibr">[24]</xref>. However, very few studies routinely collect such data, when compared to PSA. Here, we sought to investigate if PSA dynamics could be used to predict response to adaptive AA in mCRPC.</p>
              <p id="para0005">We extended our relatively simple model of PCa stem cell dynamics with previously demonstrated predictive power <xref rid="bib0001" ref-type="bibr">[1]</xref>. We calibrated and validated the model against longitudinal PSA data from 16 mCRPC patients receiving adaptive AA in a proof-of-principle prospective pilot trial (NCT02415621). We then used early treatment dynamics to predict how individual patient respond to subsequent treatment cycles. We further investigated how to integrate individual metastatic burden into the predictive modeling framework to increase patient-specific prediction accuracy. We also use the model to simulate the addition of concurrent chemotherapy in those patients predicted to progress during the second cycle of treatment.</p>
            </sec>
            <sec id="sec0002">
              <title>Materials and Methods</title>
              <sec id="sec0003">
                <title>Patient Data</title>
                <p id="para0006">Sixteen mCRPC patients received adaptive AA therapy as part of a pilot trial at Moffitt Cancer Center <xref rid="bib0005" ref-type="bibr">[5]</xref>. Prior to trial registration, patients received AA plus prednisone as standard of care. Patients who achieved a 50% or more decline of their PSA were eligible to enroll in the trial. Each patient's PSA immediately prior to beginning AA was considered as their baseline. Treatment with</p>
                <p id="para0007">AA was paused when PSA fell below 50% of the individual baseline PSA, and resumed when PSA rose above baseline levels. PSA was monitored every 4 to 6 weeks, with restaging bone scan, pelvic and abdominal CT scan performed every 12 weeks. Patients remained on the trial until radiographic progression based on PCWG2 criteria <xref rid="bib0025" ref-type="bibr">[25]</xref>.</p>
                <p id="para0008">We analyzed longitudinal PSA data (collected every 4-6 weeks both whilst receiving AA and during AA holidays) for the patients enrolled in the trial (average number of data points per patient = 24, range = 9 – 41) to evaluate early PSA response dynamics as predictive biomarker of PSA progression. PSA progression is defined as PSA increasing <inline-formula><mml:math id="M2" altimg="si7.svg"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>25</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> and at least <inline-formula><mml:math id="M3" altimg="si8.svg"><mml:mrow><mml:mn>2</mml:mn><mml:mspace width="0.33em"/><mml:mrow><mml:mtext>ng</mml:mtext><mml:mo linebreak="badbreak">/</mml:mo><mml:mtext>mL</mml:mtext></mml:mrow></mml:mrow></mml:math></inline-formula> above the nadir, confirmed by a second value 3 or more weeks later. Eight of the 16 patients developed PSA progression within the first four cycles of treatment, and eight patients were still responding after four cycles (one patient developed resistance after 9 cycles of treatment) (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>).<fig id="fig0001"><label>Fig. 1</label><caption><p><italic>Treatment times for patients included in the study</italic><bold>.</bold> Sixteen patients were included in the model analysis. Gray and white denote when treatment was on and off, respectively. Red triangles and black x's denote when patient developed PSA and radiographic progression, respectively. (Color version of figure is available online)</p></caption><alt-text id="alt0001">Fig 1</alt-text><graphic xlink:href="gr1"/></fig></p>
              </sec>
              <sec id="sec0004">
                <title>Mathematical Model</title>
                <p id="para0009">The mathematical model simulates the dynamics of prostate cancer stem-like cells (PCaSCs) (<inline-formula><mml:math id="M4" altimg="si9.svg"><mml:mi>S</mml:mi></mml:math></inline-formula>), non-stem differentiated cells (<inline-formula><mml:math id="M5" altimg="si10.svg"><mml:mi>D</mml:mi></mml:math></inline-formula>), and PSA (<inline-formula><mml:math id="M6" altimg="si11.svg"><mml:mi>P</mml:mi></mml:math></inline-formula>). PCaSCs divide at rate <inline-formula><mml:math id="M7" altimg="si12.svg"><mml:mrow><mml:mi>λ</mml:mi><mml:mspace width="0.33em"/><mml:mo>(</mml:mo><mml:mrow><mml:mtext>da</mml:mtext><mml:msup><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> to produce either a PCaSC and non-stem PCa cell with probability <inline-formula><mml:math id="M8" altimg="si13.svg"><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="goodbreak">−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> (asymmetric division) or two PCaSCs with probability <inline-formula><mml:math id="M9" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> (symmetric division), with negative feedback from the differentiated cells. Non-stem PCa cells die at rate <inline-formula><mml:math id="M10" altimg="si14.svg"><mml:mrow><mml:mi>α</mml:mi><mml:mspace width="0.33em"/><mml:mo>(</mml:mo><mml:mrow><mml:mtext>da</mml:mtext><mml:msup><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> in response to treatment, which is modulated by the parameter <inline-formula><mml:math id="M11" altimg="si15.svg"><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>x</mml:mi></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M12" altimg="si16.svg"><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>x</mml:mi></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>, denoting when treatment is on and off, respectively. PSA is produced by the non-stem PCa cells at rate <inline-formula><mml:math id="M13" altimg="si17.svg"><mml:mrow><mml:mi>ρ</mml:mi><mml:mspace width="0.33em"/><mml:mo>(</mml:mo><mml:mrow><mml:mi>μ</mml:mi><mml:mi>g</mml:mi><mml:mo linebreak="badbreak">/</mml:mo><mml:mi>L</mml:mi><mml:mspace width="0.33em"/><mml:mtext>da</mml:mtext><mml:msup><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> and decays at rate <inline-formula><mml:math id="M14" altimg="si18.svg"><mml:mrow><mml:mi>φ</mml:mi><mml:mspace width="0.33em"/><mml:mo>(</mml:mo><mml:mrow><mml:mtext>da</mml:mtext><mml:msup><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula>. The mathematical equations describing these interactions are given by<disp-formula id="eqn0001"><label>(1)</label><mml:math id="M15" altimg="si19.svg"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mi mathvariant="italic">dS</mml:mi><mml:mi mathvariant="italic">dt</mml:mi></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mi>λ</mml:mi><mml:mi>S</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mi mathvariant="italic">dD</mml:mi><mml:mi mathvariant="italic">dt</mml:mi></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">−</mml:mo><mml:mfrac><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi></mml:mrow></mml:mfrac><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mi>λ</mml:mi><mml:mi>S</mml:mi><mml:mo linebreak="goodbreak">−</mml:mo><mml:mi>α</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mi>x</mml:mi></mml:msub><mml:mi>D</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mi mathvariant="italic">dP</mml:mi><mml:mi mathvariant="italic">dt</mml:mi></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi>ρ</mml:mi><mml:mi>D</mml:mi><mml:mo linebreak="goodbreak">−</mml:mo><mml:mi>φ</mml:mi><mml:mi>P</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p>
              </sec>
              <sec id="sec0005">
                <title>Model calibration and validation</title>
                <p id="para0010">Previous analysis has shown that the rate at which uninhibited PCaSCs divide can be approximated as once a day, i.e., <inline-formula><mml:math id="M16" altimg="si20.svg"><mml:mrow><mml:mi>λ</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:mi>ln</mml:mi><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula><xref rid="bib0026" ref-type="bibr">[26]</xref>. Sensitivity and correlation analysis showed that <inline-formula><mml:math id="M17" altimg="si5.svg"><mml:mi>ρ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="M18" altimg="si4.svg"><mml:mi>φ</mml:mi></mml:math></inline-formula> could be uniform among all patients and <inline-formula><mml:math id="M19" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M20" altimg="si2.svg"><mml:mi>α</mml:mi></mml:math></inline-formula> be patient-specific without significantly changing the model results <xref rid="bib0001" ref-type="bibr">[1]</xref>. We deployed a Type 1b bootstrap internal validation leave-one-out analysis <xref rid="bib0027" ref-type="bibr">[27]</xref> to determine the uniform values for <inline-formula><mml:math id="M21" altimg="si5.svg"><mml:mi>ρ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="M22" altimg="si21.svg"><mml:mrow><mml:mi>φ</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.33em"/></mml:mrow></mml:math></inline-formula>while allowing <inline-formula><mml:math id="M23" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M24" altimg="si2.svg"><mml:mi>α</mml:mi></mml:math></inline-formula> to be patient-specific. That is, for patient <inline-formula><mml:math id="M25" altimg="si22.svg"><mml:mi>j</mml:mi></mml:math></inline-formula>, we used nested optimization to find the uniform values for <inline-formula><mml:math id="M26" altimg="si23.svg"><mml:msub><mml:mi>ρ</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M27" altimg="si24.svg"><mml:mrow><mml:msub><mml:mi>φ</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mspace width="0.33em"/></mml:mrow></mml:math></inline-formula>and the patient-specific values for <inline-formula><mml:math id="M28" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M29" altimg="si2.svg"><mml:mi>α</mml:mi></mml:math></inline-formula> for all patients <inline-formula><mml:math id="M30" altimg="si25.svg"><mml:mi>n</mml:mi></mml:math></inline-formula>, with <inline-formula><mml:math id="M31" altimg="si26.svg"><mml:mrow><mml:mi>n</mml:mi><mml:mo>≠</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula>, in the training set, over each patient's treatment course. We then validated the model using <inline-formula><mml:math id="M32" altimg="si23.svg"><mml:msub><mml:mi>ρ</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M33" altimg="si24.svg"><mml:msub><mml:mi>φ</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula> to determine the patient-specific <inline-formula><mml:math id="M34" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M35" altimg="si2.svg"><mml:mi>α</mml:mi></mml:math></inline-formula> for patient <inline-formula><mml:math id="M36" altimg="si22.svg"><mml:mi>j</mml:mi></mml:math></inline-formula>. This process was repeated for all <inline-formula><mml:math id="M37" altimg="si27.svg"><mml:mrow><mml:mi>N</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:mn>16</mml:mn></mml:mrow></mml:math></inline-formula> patients.</p>
              </sec>
              <sec id="sec0006">
                <title>Treatment response prediction</title>
                <p id="para0011">For patient <inline-formula><mml:math id="M38" altimg="si22.svg"><mml:mi>j</mml:mi></mml:math></inline-formula>, <inline-formula><mml:math id="M39" altimg="si23.svg"><mml:msub><mml:mi>ρ</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M40" altimg="si24.svg"><mml:msub><mml:mi>φ</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula> were used to fit the model to each cycle individually for all patients in the training set. That is, finding the optimal value for <inline-formula><mml:math id="M41" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M42" altimg="si2.svg"><mml:mi>α</mml:mi></mml:math></inline-formula> while allowing <inline-formula><mml:math id="M43" altimg="si23.svg"><mml:msub><mml:mi>ρ</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M44" altimg="si24.svg"><mml:msub><mml:mi>φ</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula> to remain fixed for each individual cycle (<xref rid="fig0002" ref-type="fig">Fig. 2</xref><bold>A</bold>). Given <inline-formula><mml:math id="M45" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M46" altimg="si2.svg"><mml:mi>α</mml:mi></mml:math></inline-formula> for cycle <inline-formula><mml:math id="M47" altimg="si28.svg"><mml:mi>i</mml:mi></mml:math></inline-formula> for patient <inline-formula><mml:math id="M48" altimg="si22.svg"><mml:mi>j</mml:mi></mml:math></inline-formula>, we used the relative changes in <inline-formula><mml:math id="M49" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> for all patients in our training set to generate the cumulative probability distribution of relative changes in <inline-formula><mml:math id="M50" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> from cycle <inline-formula><mml:math id="M51" altimg="si28.svg"><mml:mi>i</mml:mi></mml:math></inline-formula> to cycle <inline-formula><mml:math id="M52" altimg="si29.svg"><mml:mrow><mml:mi>i</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> (<xref rid="fig0002" ref-type="fig">Fig. 2</xref><bold>B</bold>). We sampled from this distribution to determine 100 values of <inline-formula><mml:math id="M53" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> for cycle <inline-formula><mml:math id="M54" altimg="si30.svg"><mml:mrow><mml:mi>i</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo><mml:mspace width="0.33em"/></mml:mrow></mml:math></inline-formula>As <inline-formula><mml:math id="M55" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M56" altimg="si2.svg"><mml:mi>α</mml:mi></mml:math></inline-formula> are exponentially related <xref rid="bib0001" ref-type="bibr">[1]</xref>, we sampled from the 95% confidence interval around the exponential curve relating <inline-formula><mml:math id="M57" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M58" altimg="si2.svg"><mml:mi>α</mml:mi></mml:math></inline-formula> (<xref rid="fig0002" ref-type="fig">Fig. 2</xref><bold>C</bold>) to find 100 values for <inline-formula><mml:math id="M59" altimg="si31.svg"><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>. We used these values to simulate the distribution of patient <inline-formula><mml:math id="M60" altimg="si22.svg"><mml:mi>j</mml:mi></mml:math></inline-formula>’s responses in cycle <inline-formula><mml:math id="M61" altimg="si29.svg"><mml:mrow><mml:mi>i</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>.<fig id="fig0002"><label>Fig. 2</label><caption><p><italic>Cycle by cycle parameter changes</italic><bold>. (A)</bold> Parameter distributions of <inline-formula><mml:math id="M62" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula>for Cycles 1 through 4. <bold>(B)</bold> Cumulative probability distribution of relative changes in <inline-formula><mml:math id="M63" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> from Cycle 1 to Cycle 2. <bold>(C)</bold><inline-formula><mml:math id="M64" altimg="si2.svg"><mml:mi>α</mml:mi></mml:math></inline-formula> vs. <inline-formula><mml:math id="M65" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> fit (black curve) and 95% confidence interval (gray) for (<inline-formula><mml:math id="M66" altimg="si3.svg"><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.33em"/><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>) pairs (black dots) for Cycle 2.</p></caption><alt-text id="alt0002">Fig 2</alt-text><graphic xlink:href="gr2"/></fig></p>
                <p id="para0012">Each model simulation was determined to predict response or resistance based on the PSA progression criteria defined in the trial. That is, if PSA increased more than 25% and at least 2 <inline-formula><mml:math id="M67" altimg="si32.svg"><mml:mrow><mml:mtext>ng</mml:mtext><mml:mo linebreak="goodbreak">/</mml:mo><mml:mtext>mL</mml:mtext></mml:mrow></mml:math></inline-formula> above the nadir during treatment, then the simulation was classified as resistant. Of the 100 response simulations, we quantified the number of resistant simulations to derive a probability of resistance, <inline-formula><mml:math id="M68" altimg="si33.svg"><mml:mrow><mml:mi>Pr</mml:mi><mml:mo>(</mml:mo><mml:mstyle mathvariant="normal"><mml:mi>Ω</mml:mi></mml:mstyle><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula>. If <inline-formula><mml:math id="M69" altimg="si33.svg"><mml:mrow><mml:mi>Pr</mml:mi><mml:mo>(</mml:mo><mml:mstyle mathvariant="normal"><mml:mi>Ω</mml:mi></mml:mstyle><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> was greater than a given threshold, <inline-formula><mml:math id="M70" altimg="si34.svg"><mml:msub><mml:mi>κ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula>, obtained from the training set for each predicted treatment cycle <inline-formula><mml:math id="M71" altimg="si28.svg"><mml:mi>i</mml:mi></mml:math></inline-formula>, then the prediction was considered resistant. Otherwise, it was classified as responsive. For each leave-one-out patient, an optimal cutoff value <inline-formula><mml:math id="M72" altimg="si35.svg"><mml:msub><mml:mi>k</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula> for cycle <inline-formula><mml:math id="M73" altimg="si28.svg"><mml:mi>i</mml:mi></mml:math></inline-formula>was determined to be the threshold that maximized the accuracy within the training set. Model predictions correctly classifying clinically observed responders as responders (<inline-formula><mml:math id="M74" altimg="si36.svg"><mml:mrow><mml:mi>Pr</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mstyle mathvariant="normal"><mml:mi>Ω</mml:mi></mml:mstyle><mml:mo>)</mml:mo></mml:mrow><mml:mo linebreak="goodbreak">&lt;</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> were denoted true negative, while correctly classified clinically resistors (<inline-formula><mml:math id="M75" altimg="si37.svg"><mml:mrow><mml:mi>Pr</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mstyle mathvariant="normal"><mml:mi>Ω</mml:mi></mml:mstyle><mml:mo>)</mml:mo></mml:mrow><mml:mo linebreak="goodbreak">&gt;</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> were denoted as true positive.</p>
              </sec>
              <sec id="sec0007">
                <title>Statistical analysis</title>
                <p id="para0013">The two-sample t-test was used to calculate the statistical significance of the difference between parameter distributions.</p>
              </sec>
            </sec>
            <sec id="sec0008">
              <title>Results</title>
              <sec id="sec0009">
                <title>Model accurately describes clinical data</title>
                <p id="para0014">The model is able to simulate longitudinal PSA data from mCRPC patients (<xref rid="fig0003" ref-type="fig">Fig. 3</xref><bold>A-B</bold>). In line with previous results of intermittent ADT <xref rid="bib0001" ref-type="bibr">[1]</xref>, the model fits to the data demonstrate that continuous responders have a slowly increasing PCaSC population (<xref rid="fig0003" ref-type="fig">Fig. 3</xref><bold>A</bold>), while patients who progress have a rapidly increasing PCaSC population (<xref rid="fig0003" ref-type="fig">Fig. 3</xref><bold>B</bold>). This shows that prostate cancer stem cell enrichment is a plausible driver of resistance to AA therapy. A comparison of the stem cell self-renewal rate <inline-formula><mml:math id="M76" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> between responsive and resistant patients showed that resistant patients tend to have a larger <inline-formula><mml:math id="M77" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> value, though not significant in this small cohort (<xref rid="fig0003" ref-type="fig">Fig. 3</xref><bold>C</bold>). No difference in the uniform values for <inline-formula><mml:math id="M78" altimg="si5.svg"><mml:mi>ρ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="M79" altimg="si4.svg"><mml:mi>φ</mml:mi></mml:math></inline-formula> for each leave-one-out analysis were found (<xref rid="fig0003" ref-type="fig">Fig. 3</xref><bold>D</bold>).<fig id="fig0003"><label>Fig. 3</label><caption><p><italic>Leave-one-out analysis results</italic><bold>.</bold> Model fits to PSA data and corresponding stem cell dynamics for a <bold>(A)</bold> continuous responder and <bold>(B)</bold> a patient who developed resistance in his third cycle of treatment. Parameter distributions for <bold>(C)</bold> patient-specific parameters <inline-formula><mml:math id="M80" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M81" altimg="si2.svg"><mml:mi>α</mml:mi></mml:math></inline-formula> and <bold>(D)</bold> uniform model parameters <inline-formula><mml:math id="M82" altimg="si4.svg"><mml:mi>φ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="M83" altimg="si5.svg"><mml:mi>ρ</mml:mi></mml:math></inline-formula> determined via leave-one-out analysis.</p></caption><alt-text id="alt0003">Fig 3</alt-text><graphic xlink:href="gr3"/></fig></p>
              </sec>
              <sec id="sec0010">
                <title>Early treatment dynamics can predict subsequent response</title>
                <p id="para0015">Model predictions are classified as true positive, true negative, false positive and false negative in comparison to the clinical outcomes (<xref rid="fig0004" ref-type="fig">Fig. 4</xref><bold>A</bold>). Model predictions for a continuous responder and a patient who progressed in the third cycle are shown in <xref rid="fig0004" ref-type="fig">Fig. 4</xref><bold>B-C</bold>. The model was fit over the first treatment cycle using the <inline-formula><mml:math id="M84" altimg="si5.svg"><mml:mi>ρ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="M85" altimg="si4.svg"><mml:mi>φ</mml:mi></mml:math></inline-formula> values obtained from the training set. Using the relative change in <inline-formula><mml:math id="M86" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> from cycle <inline-formula><mml:math id="M87" altimg="si28.svg"><mml:mi>i</mml:mi></mml:math></inline-formula> to cycle <inline-formula><mml:math id="M88" altimg="si29.svg"><mml:mrow><mml:mi>i</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> as well as the exponential relationship between <inline-formula><mml:math id="M89" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M90" altimg="si2.svg"><mml:mi>α</mml:mi></mml:math></inline-formula>, we obtained 100 parameter pairs of (<inline-formula><mml:math id="M91" altimg="si38.svg"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>) that were used to forecast the patient's response in the subsequent cycle. The model accurately predicted that Patient 1011 would continue to respond in both the second and third cycles (<xref rid="fig0004" ref-type="fig">Fig. 4</xref><bold>B</bold>). Patient 1014 progressed in his third cycle of treatment. Though <inline-formula><mml:math id="M92" altimg="si39.svg"><mml:mrow><mml:mi>Pr</mml:mi><mml:mo>(</mml:mo><mml:mstyle mathvariant="normal"><mml:mi>Ω</mml:mi></mml:mstyle><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mn>0.49</mml:mn></mml:mrow></mml:math></inline-formula> in cycle 2, this is below the threshold <inline-formula><mml:math id="M93" altimg="si40.svg"><mml:msub><mml:mi>κ</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math></inline-formula> and consequently the model correctly predicts that this patient will continue to respond. In cycle 3, <inline-formula><mml:math id="M94" altimg="si41.svg"><mml:mrow><mml:mi>Pr</mml:mi><mml:mo>(</mml:mo><mml:mstyle mathvariant="normal"><mml:mi>Ω</mml:mi></mml:mstyle><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mn>0.70</mml:mn></mml:mrow></mml:math></inline-formula> which is larger than <inline-formula><mml:math id="M95" altimg="si42.svg"><mml:msub><mml:mi>κ</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:math></inline-formula>. This is a correct prediction as Patient 1014 develops resistance in cycle 3. Overall, the model is able to correctly predict patient response with 78% accuracy (specificity = 92%, sensitivity = 38%).<fig id="fig0004"><label>Fig. 4</label><caption><p><italic>Model prediction results</italic><bold>. (A)</bold> Prediction classifier table. Model predictions for <bold>(B)</bold> Patient 1011 who was a continuous responder and <bold>(C)</bold> Patient 1014 who progressed in the third cycle. The model correctly predicted that Patient 1011 would continue to respond in both the second and third cycles and that Patient 1014 would continue to respond in the second cycle and develop resistance in the third cycle. Prediction classifications are determined using cycle- and patient-specific κ values. If the P(Ω) &gt; κ, then the patient is predicted to develop resistance. Model predictions were compared to actual data to determine accuracy.</p></caption><alt-text id="alt0004">Fig 4</alt-text><graphic xlink:href="gr4"/></fig></p>
              </sec>
              <sec id="sec0011">
                <title>Incorporating metastatic burden</title>
                <p id="para0016">Despite treatment, several patients continued to develop metastases during the trial. Though rising PSA has been shown to be correlated with metastatic burden, it is not predictive of the development of new metastatic growths <xref rid="bib0028" ref-type="bibr">[28]</xref>. We sought to investigate whether correlating metastatic growth with the stem cell self-renewal rate, <inline-formula><mml:math id="M96" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula>, would improve the prediction accuracy of our model. That is, developing new metastatic growths during a cycle of treatment is likely the consequence of a larger number of anatomically distributed PCaSCs, whose dynamics are primarily driven by the self-renewal rate <inline-formula><mml:math id="M97" altimg="si43.svg"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></inline-formula> Thus, we propose a novel way to correlate new metastatic growths with <inline-formula><mml:math id="M98" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula>.</p>
                <p id="para0017">As previously described, (<inline-formula><mml:math id="M99" altimg="si38.svg"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>) pairs for cycle <inline-formula><mml:math id="M100" altimg="si29.svg"><mml:mrow><mml:mi>i</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mn>1</mml:mn><mml:mspace width="0.33em"/></mml:mrow></mml:math></inline-formula>were obtained by uniformly sampling from the cumulative probability distribution of relative changes in <inline-formula><mml:math id="M101" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> from cycle <inline-formula><mml:math id="M102" altimg="si28.svg"><mml:mi>i</mml:mi></mml:math></inline-formula> to <inline-formula><mml:math id="M103" altimg="si29.svg"><mml:mrow><mml:mi>i</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>. <xref rid="fig0005" ref-type="fig">Fig. 5</xref><bold>A</bold> shows that in general, the relative change ranged between -75% and 150%, with about 30% of the patients experiencing larger relative changes in <inline-formula><mml:math id="M104" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula>. To incorporate the metastatic burden, we used a skewed sampling to sample from the cumulative probability distribution, with the degree of the skew dependent on the number of new metastatic growths. This resulted in larger relative increases in <inline-formula><mml:math id="M105" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> for patients with larger metastatic burden<inline-formula><mml:math id="M106" altimg="si44.svg"><mml:mo>.</mml:mo></mml:math></inline-formula> As shown in <xref rid="fig0003" ref-type="fig">Fig. 3</xref><bold>C</bold>, patients with larger <inline-formula><mml:math id="M107" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> developed resistance to adaptive AA faster in comparison to those with smaller <inline-formula><mml:math id="M108" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> values. Consequently, the skewed sampling results in a larger fraction of simulations that predict resistance, thereby increasing the <inline-formula><mml:math id="M109" altimg="si45.svg"><mml:mrow><mml:mi>Pr</mml:mi><mml:mo>(</mml:mo><mml:mstyle mathvariant="normal"><mml:mi>Ω</mml:mi></mml:mstyle><mml:mo>)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></inline-formula> It should be noted that this also resulted in <inline-formula><mml:math id="M110" altimg="si34.svg"><mml:msub><mml:mi>κ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula> changing in response to larger <inline-formula><mml:math id="M111" altimg="si33.svg"><mml:mrow><mml:mtext>Pr</mml:mtext><mml:mo>(</mml:mo><mml:mstyle mathvariant="normal"><mml:mi>Ω</mml:mi></mml:mstyle><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> for particular patients within the training cohort.<fig id="fig0005"><label>Fig. 5</label><caption><p><italic>Model prediction results when considering metastatic burden.</italic><bold>(A)</bold> Parameter sampling with and without metastases. When a patient's metastatic burden is not considered, a uniform sampling is performed to determine <inline-formula><mml:math id="M112" altimg="si1.svg"><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></inline-formula> value in next cycle. If a patient develops a new metastatic growth, the sampling is skewed such that the sampled stem cell self-renewal value is more likely to be larger in the next cycle. <bold>(B)</bold> Model predictions for Patient 1010 with and without incorporating metastatic burden. Patient 1010 developed on new metastatic growth during his first off-treatment cycle. Using PSA dynamics alone, the model incorrectly predicts that Patient 1010 will continue to respond. Using a skewed sampling results in a correct prediction that Patient 1010 will progress in cycle 2.</p></caption><alt-text id="alt0005">Fig 5</alt-text><graphic xlink:href="gr5"/></fig></p>
                <p id="para0018">A comparison between the model predictions using a uniform and skewed sampling for an individual patient are shown in <xref rid="fig0005" ref-type="fig">Fig. 5</xref><bold>B</bold>. Patient 1010 developed a new metastatic growth during his first cycle of treatment. With a uniform sampling, the model predicted that the <inline-formula><mml:math id="M113" altimg="si46.svg"><mml:mrow><mml:mi>Pr</mml:mi><mml:mo>(</mml:mo><mml:mstyle mathvariant="normal"><mml:mi>Ω</mml:mi></mml:mstyle><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mn>0.47</mml:mn><mml:mo>.</mml:mo><mml:mspace width="0.33em"/></mml:mrow></mml:math></inline-formula>As this was below the threshold <inline-formula><mml:math id="M114" altimg="si40.svg"><mml:msub><mml:mi>κ</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math></inline-formula>, the model incorrectly predicted that this patient would continue to respond in the second cycle (false negative). Using a skewed sampling, the <inline-formula><mml:math id="M115" altimg="si33.svg"><mml:mrow><mml:mi>Pr</mml:mi><mml:mo>(</mml:mo><mml:mstyle mathvariant="normal"><mml:mi>Ω</mml:mi></mml:mstyle><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> increased to 0.53, which was larger than the new threshold <inline-formula><mml:math id="M116" altimg="si40.svg"><mml:msub><mml:mi>κ</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math></inline-formula> resulting in a correct resistant prediction (true positive). Overall, incorporating each patient's metastatic increased the accuracy to 81% (specificity = 92%, sensitivity = 50%).</p>
              </sec>
              <sec id="sec0012">
                <title>Concurrent chemotherapy can improve time to progression</title>
                <p id="para0019">Concurrently administering the chemotherapeutic docetaxel with ADT has shown benefit in metastatic hormone-naïve prostate cancer patients <xref rid="bib0029" ref-type="bibr">[29]</xref>, <xref rid="bib0030" ref-type="bibr">[30]</xref>, <xref rid="bib0031" ref-type="bibr">[31]</xref>. In particular, the STAMPEDE trial conducted in 2016 showed a 10 month increase in overall survival in high-risk, locally advanced PCa patients receiving ADT with docetaxel compared to ADT alone <xref rid="bib0031" ref-type="bibr">[31]</xref>. Cabazitaxel is a second-line chemotherapeutic that has shown survival benefit after progression on docetaxel and is often given as standard of care after AA <xref rid="bib0032" ref-type="bibr">[32]</xref>. As previous studies have shown that chemotherapy provides more benefit when administered earlier in the disease course, we sought to investigate the effect of administering concurrent chemotherapy prior to progression on AA alone.</p>
                <p id="para0020">Unlike AA, chemotherapy can induce cell death in both PCaSCs and non-stem cells <xref rid="bib0033" ref-type="bibr">[33]</xref>. As such, we extended our model to include death terms (<inline-formula><mml:math id="M117" altimg="si47.svg"><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi>S</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mspace width="0.33em"/><mml:msub><mml:mi>δ</mml:mi><mml:mi>D</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>) on both cell populations in response to chemotherapy (<inline-formula><mml:math id="M118" altimg="si48.svg"><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi>x</mml:mi><mml:mi>D</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>). That is,<disp-formula id="eqn0002"><label>(2)</label><mml:math id="M119" altimg="si49.svg"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mi mathvariant="italic">dS</mml:mi><mml:mi mathvariant="italic">dt</mml:mi></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mi>λ</mml:mi><mml:mi>S</mml:mi><mml:mo linebreak="goodbreak">−</mml:mo><mml:mspace width="0.33em"/><mml:msub><mml:mi>δ</mml:mi><mml:mi>S</mml:mi></mml:msub><mml:msub><mml:mi>T</mml:mi><mml:mi mathvariant="italic">xD</mml:mi></mml:msub><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.33em"/></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mi mathvariant="italic">dD</mml:mi><mml:mi mathvariant="italic">dt</mml:mi></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">−</mml:mo><mml:mfrac><mml:mi>S</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi></mml:mrow></mml:mfrac><mml:msub><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mi>λ</mml:mi><mml:mi>S</mml:mi><mml:mo linebreak="goodbreak">−</mml:mo><mml:mi>α</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mi>x</mml:mi></mml:msub><mml:mi>D</mml:mi><mml:mo linebreak="goodbreak">−</mml:mo><mml:mspace width="0.33em"/><mml:msub><mml:mi>δ</mml:mi><mml:mi>D</mml:mi></mml:msub><mml:msub><mml:mi>T</mml:mi><mml:mi mathvariant="italic">xD</mml:mi></mml:msub><mml:mi>D</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.33em"/></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mi mathvariant="italic">dP</mml:mi><mml:mi mathvariant="italic">dt</mml:mi></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi>ρ</mml:mi><mml:mi>D</mml:mi><mml:mo linebreak="goodbreak">−</mml:mo><mml:mi>φ</mml:mi><mml:mi>P</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p>
                <p id="para0021">Due to the patients included in our study being chemotherapy-naïve, we did not have clinical data to calibrate the model to obtain values for <inline-formula><mml:math id="M120" altimg="si50.svg"><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">S</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M121" altimg="si51.svg"><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">D</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></inline-formula> Consequently, the values for these parameters were derived from literature, where it is said that approximately three times more non-stem cells die in response to chemotherapy than PCaSCs<xref rid="bib0033" ref-type="bibr">[33]</xref>. We chose <inline-formula><mml:math id="M122" altimg="si52.svg"><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">S</mml:mi></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:mspace width="0.33em"/><mml:mn>0.0027</mml:mn><mml:mspace width="0.33em"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>da</mml:mtext><mml:msup><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M123" altimg="si53.svg"><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">D</mml:mi></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:mspace width="0.33em"/><mml:mn>0.008</mml:mn><mml:mspace width="0.33em"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>da</mml:mtext><mml:msup><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> such that model simulations would show a decline in each population when chemotherapy was given.</p>
                <p id="para0022">For the patients predicted to progress during their second cycle of adaptive therapy, we simulated adding up to 10 cycles of concurrent chemotherapy during cycle two and compared the responses with and without chemotherapy (<xref rid="fig0006" ref-type="fig">Fig. 6</xref>). While some patients received minimal benefit (3% decrease in <inline-formula><mml:math id="M124" altimg="si54.svg"><mml:mrow><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mstyle mathvariant="normal"><mml:mi>Ω</mml:mi></mml:mstyle><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> Patient 1015) from concurrent therapy, others received as much as an 11% decrease in <inline-formula><mml:math id="M125" altimg="si55.svg"><mml:mrow><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mstyle mathvariant="normal"><mml:mi>Ω</mml:mi></mml:mstyle><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> with concurrent treatment (Patient 1005).<fig id="fig0006"><label>Fig. 6</label><caption><p><italic>Model simulation comparison between adaptive abiraterone with and without concurrent chemotherapy.</italic> (A) Without concurrent chemotherapy, Patient 1015 is predicted to have a 58% probability of developing resistance in his second cycle of treatment (left). Concurrent chemotherapy (right) provides a minimal reduction (3%) in the probability of developing resistance. (B) Patient 1005 has a 79% probability of progressing during cycle 2 without concurrent chemotherapy (left). This can be reduced by 11% if chemotherapy is given concurrently during cycle 2 (right).</p></caption><alt-text id="alt0006">Fig 6</alt-text><graphic xlink:href="gr6"/></fig></p>
              </sec>
            </sec>
            <sec id="sec0013">
              <title>Discussion</title>
              <p id="para0023">In this study, we have analyzed a simple mathematical model of PCaSC and PSA dynamics to predict individual mCRPC patient responses to adaptive AA therapy. The model has been calibrated and validated against clinical data from 16 mCRPC patients from a pilot trial. With just two patient-specific parameters, our results show that the model is able to accurately describe individual patient dynamics. Similar to previous analyses of PCa stem cell dynamics underlying resistance to intermittent ADT, we found that stem cell enrichment is a likely driver of treatment resistance, despite AA working through an alternative pathway than ADT <xref rid="bib0009" ref-type="bibr">[9]</xref>. As these patients are advanced metastatic PCa patients, their PSA dynamics are likely also driven by multiple factors that the model may not be able to account for. Despite that, the model was able to use early treatment evolutionary PSA dynamics to predict subsequent responses with 78% accuracy.</p>
              <p id="para0024">Incorporating the metastatic burden improved the overall accuracy to 82%, with a specificity of 92% and a sensitivity of 50%. The lower sensitivity is due to the few progression events within this data cohort. While patients respond on average for 3.3 treatment cycles, the majority of progression events occurred within the second cycle. This limitation made it difficult to determine the optimal threshold value for cycle predictions where few patients progressed, resulting in a higher proportion of false negative results. We are confident that model accuracy, as well as sensitivity and specificity, would increase with a larger patient cohort. Nevertheless, the patients who were incorrectly predicted to develop resistance during the second cycle instead progressed during the third cycle. As such, the model may serve as an early indicator of treatment resistance for a subset of patients.</p>
              <p id="para0025">We also investigated the potential benefit of concurrent chemotherapy with AA prior to progression on AA alone. Model simulations showed a 3% to 11% decrease in the probability of resistance when compared to AA alone. While 3% may be dismissed mathematically, it may mean a difference for individual patients based on their individual risk-benefit situation; as such the model predicted probabilities may provide invaluable information for the clinician to discuss with each patient when deciding if, when and how to adapt treatment. Using the presented model, the oncologist can discuss different treatment routes with associated risk and likelihood of success to guide patients decide what is the best course of action for their individual treatment expectations. As such, we believe that this is an option that should be considered for patients and warrants critical evaluation in a prospective clinical trial setting. We do note that the concurrent chemotherapy simulations used chemotherapy sensitivity parameters (<inline-formula><mml:math id="M126" altimg="si56.svg"><mml:msub><mml:mi>δ</mml:mi><mml:mi>S</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M127" altimg="si57.svg"><mml:msub><mml:mi>δ</mml:mi><mml:mi>D</mml:mi></mml:msub></mml:math></inline-formula>) that were not previously calibrated to clinical data. Future studies will include calibrating the model to clinical data of patients receiving concurrent chemotherapy to determine the values for these parameters that can be used in further model simulations.</p>
              <p id="para0026">As previously mentioned, alternative biomarkers such as ctDNA, cfDNA, and PCa stem cell antigen (PSCA) and other stem cell markers have been shown to be correlated with advanced PCa and metastasis [<xref rid="bib0021" ref-type="bibr">[21]</xref>, <xref rid="bib0022" ref-type="bibr">[22]</xref>, <xref rid="bib0023" ref-type="bibr">[23]</xref>, <xref rid="bib0024" ref-type="bibr">[24]</xref>,<xref rid="bib0034" ref-type="bibr">34</xref>]. However, due to the lack of availability of data, we were not able to design our model based on these dynamics. Collecting and analyzing such biomarkers are promising future avenues for clinical studies and mathematical modeling.</p>
            </sec>
            <sec id="sec0014">
              <title>Conclusions</title>
              <p id="para0027">This validation study demonstrates the utility of mathematical modeling in clinical decision making. Using a simple dynamic model of PCaSC, non-stem cells, and PSA, we are able to use early treatment dynamics to predict who may or may not respond to subsequent treatment in mCRPC. Despite PSA notoriously being considered a poor biomarker for treatment response, both in early- and advanced-stage prostate cancer, we showed that our model could use PSA dynamics – rather than absolute PSA values – to predict response with an 81% accuracy. Our model is the first of its kind to correlate PSA dynamics with metastatic burden to understand how an individual patient's disease is evolving. As this model predicts PSA, and not radiographic progression, this may provide sufficient lead-in time for clinicians to intercede with alternative treatment options prior to radiographic progression, potentially minimizing adverse events and toxicity and maximizing survival. After prospective validation, such integrated approach could equip clinicians with an additional decision support tool to use when deciding how to effectively treat patients.</p>
            </sec>
            <sec id="sec0015">
              <title>Author Contributions</title>
              <p id="para0028">R.B.N., J.Z., R.A.G. and H.E. conceptualized the study. R.B.N. and H.</p>
              <p id="para0029">E. performed the modeling and statistical analyses. R.B.N., J.Z., T.Z., A.Z.W., R.B., R.A.G. and</p>
              <p id="para0030">H.E. wrote the manuscript.</p>
            </sec>
            <sec id="sec0016">
              <title>Acknowledgements</title>
              <p id="para0031">We thank the participants of the clinical trial. This work was supported by <funding-source id="gs0001">NIH</funding-source>/<funding-source id="gs0002">NCI</funding-source> R21CA234787 “Predicting patient-specific responses to personalize ADT for prostate cancer”, and in part by <funding-source id="gs0003">NIH</funding-source>/<funding-source id="gs0004">NCI</funding-source> U54CA143970-05 (<funding-source id="gs0005">Physical Science Oncology Network</funding-source>) “Cancer as a complex adaptive system”, the Ocala Royal Dames for Cancer Research, Inc., and The JAYNE KOSKINAS TED GIOVANIS FOUNDATION FOR HEALTH AND POLICY, a Maryland private foundation dedicated to effecting change in health care for the public good. The opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and not necessarily represent the official views of the National Institutes of Health, the Ocala Royal Dames for Cancer Research, or the JAYNE KOSKINAS TED GIOVANIS FOUNDATION FOR HEALTH AND POLICY, its directors, officers, or staff.</p>
            </sec>
          </body>
          <back>
            <ref-list id="cebibl1">
              <title>References</title>
              <ref id="bib0001">
                <label>1</label>
                <element-citation publication-type="journal" id="sbref0001">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brady-Nicholls</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Nagy</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Gerke</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>AZ</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation</article-title>
                  <source>Nat Commun</source>
                  <volume>11</volume>
                  <year>2020</year>
                  <fpage>1750</fpage>
                  <pub-id pub-id-type="pmid">32273504</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0002">
                <label>2</label>
                <element-citation publication-type="journal" id="sbref0002">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Siegel</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Miller</surname>
                      <given-names>KD</given-names>
                    </name>
                    <name>
                      <surname>Fuchs</surname>
                      <given-names>HE</given-names>
                    </name>
                    <name>
                      <surname>Jemal</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Cancer Statistics, 2021</article-title>
                  <source>CA Cancer J Clin</source>
                  <volume>71</volume>
                  <year>2021</year>
                  <fpage>7</fpage>
                  <lpage>33</lpage>
                  <pub-id pub-id-type="pmid">33433946</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0003">
                <label>3</label>
                <element-citation publication-type="journal" id="sbref0003">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Damodaran</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kyriakopoulos</surname>
                      <given-names>CE</given-names>
                    </name>
                    <name>
                      <surname>Jarrard</surname>
                      <given-names>DF.</given-names>
                    </name>
                  </person-group>
                  <article-title>Newly diagnosed metastatic prostate cancer: has the paradigm changed?</article-title>
                  <source>Urol Clin North Am</source>
                  <volume>44</volume>
                  <year>2017</year>
                  <fpage>611</fpage>
                  <lpage>621</lpage>
                  <pub-id pub-id-type="pmid">29107277</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0004">
                <label>4</label>
                <element-citation publication-type="journal" id="sbref0004">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Harris</surname>
                      <given-names>WP</given-names>
                    </name>
                    <name>
                      <surname>Mostaghel</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Nelson</surname>
                      <given-names>PS</given-names>
                    </name>
                    <name>
                      <surname>Montgomery</surname>
                      <given-names>B.</given-names>
                    </name>
                  </person-group>
                  <article-title>Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion</article-title>
                  <source>Nat Clin Pract Urol</source>
                  <volume>6</volume>
                  <year>2009</year>
                  <fpage>76</fpage>
                  <lpage>85</lpage>
                  <pub-id pub-id-type="pmid">19198621</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0005">
                <label>5</label>
                <element-citation publication-type="journal" id="sbref0005">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhang</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Cunningham</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Gatenby</surname>
                      <given-names>RA.</given-names>
                    </name>
                  </person-group>
                  <article-title>Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer</article-title>
                  <source>Nat Commun</source>
                  <volume>8</volume>
                  <year>2017</year>
                  <fpage>1816</fpage>
                  <pub-id pub-id-type="pmid">29180633</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0006">
                <label>6</label>
                <element-citation publication-type="journal" id="sbref0006">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bruchovsky</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Klotz</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Crook</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Malone</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ludgate</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Morris</surname>
                      <given-names>WJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters</article-title>
                  <source>Cancer</source>
                  <volume>107</volume>
                  <year>2006</year>
                  <fpage>389</fpage>
                  <lpage>395</lpage>
                  <pub-id pub-id-type="pmid">16783817</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0007">
                <label>7</label>
                <element-citation publication-type="journal" id="sbref0007">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Crook</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>O’Callaghan</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Duncan</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Dearnaley</surname>
                      <given-names>DP</given-names>
                    </name>
                    <name>
                      <surname>Higano</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Horwitz</surname>
                      <given-names>EM</given-names>
                    </name>
                  </person-group>
                  <article-title>Intermittent androgen suppression for rising PSA level after radiotherapy</article-title>
                  <source>N Engl J Med</source>
                  <volume>367</volume>
                  <year>2012</year>
                  <fpage>895</fpage>
                  <lpage>903</lpage>
                  <pub-id pub-id-type="pmid">22931259</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0008">
                <label>8</label>
                <element-citation publication-type="journal" id="sbref0008">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hussain</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tangem</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Berry</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Higano</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Crawford</surname>
                      <given-names>ED</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Intermittent versus continuous androgen deprivation in prostate cancer</article-title>
                  <source>N Engl J Med</source>
                  <volume>368</volume>
                  <year>2013</year>
                  <fpage>1314</fpage>
                  <lpage>1325</lpage>
                  <pub-id pub-id-type="pmid">23550669</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0009">
                <label>9</label>
                <element-citation publication-type="journal" id="sbref0009">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ryan</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>de Bono</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Molina</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Logothetis</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>de Souza</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Abiraterone in metastatic prostate cancer without previous chemotherapy</article-title>
                  <source>N Engl J Med</source>
                  <volume>368</volume>
                  <year>2013</year>
                  <fpage>138</fpage>
                  <lpage>148</lpage>
                  <pub-id pub-id-type="pmid">23228172</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0010">
                <label>10</label>
                <element-citation publication-type="journal" id="sbref0010">
                  <person-group person-group-type="author">
                    <name>
                      <surname>de Bono</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Logothetis</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Molina</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Fizazi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>North</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Chu</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>Abiraterone and increased survival in metastatic prostate cancer</article-title>
                  <source>N Engl J Med</source>
                  <volume>364</volume>
                  <year>2011</year>
                  <fpage>1995</fpage>
                  <lpage>2005</lpage>
                  <pub-id pub-id-type="pmid">21612468</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0011">
                <label>11</label>
                <element-citation publication-type="journal" id="sbref0011">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fizazi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Tran</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Enrique Fein</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Matsubara</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Rodriguez-Antolin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Alekseev</surname>
                      <given-names>BY</given-names>
                    </name>
                  </person-group>
                  <article-title>LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <volume>35</volume>
                  <year>2017</year>
                  <fpage>LBA3</fpage>
                </element-citation>
              </ref>
              <ref id="bib0012">
                <label>12</label>
                <element-citation publication-type="journal" id="sbref0012">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hoyle</surname>
                      <given-names>AP</given-names>
                    </name>
                    <name>
                      <surname>Ali</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>James</surname>
                      <given-names>ND</given-names>
                    </name>
                    <name>
                      <surname>Cook</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Parker</surname>
                      <given-names>CC</given-names>
                    </name>
                    <name>
                      <surname>de Bono</surname>
                      <given-names>JS</given-names>
                    </name>
                  </person-group>
                  <article-title>Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer</article-title>
                  <source>Eur Urol</source>
                  <volume>76</volume>
                  <year>2019</year>
                  <fpage>719</fpage>
                  <lpage>728</lpage>
                  <pub-id pub-id-type="pmid">31447077</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0013">
                <label>13</label>
                <element-citation publication-type="journal" id="sbref0013">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rathkopf</surname>
                      <given-names>DE</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>de Bono</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Logothetis</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Shore</surname>
                      <given-names>ND</given-names>
                    </name>
                    <name>
                      <surname>de Souza</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)</article-title>
                  <source>Eur Urol</source>
                  <volume>66</volume>
                  <year>2014</year>
                  <fpage>815</fpage>
                  <lpage>825</lpage>
                  <pub-id pub-id-type="pmid">24647231</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0014">
                <label>14</label>
                <element-citation publication-type="journal" id="sbref0014">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baez</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kuang</surname>
                      <given-names>Y.</given-names>
                    </name>
                  </person-group>
                  <article-title>Mathematical models of androgen resistance in prostate cancer patients under intermittent androgen suppression therapy</article-title>
                  <source>Appl Sci</source>
                  <volume>6</volume>
                  <year>2016</year>
                  <fpage>352</fpage>
                </element-citation>
              </ref>
              <ref id="bib0015">
                <label>15</label>
                <element-citation publication-type="journal" id="sbref0015">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Elishmereni</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kheifetz</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Shukrun</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Bevan</surname>
                      <given-names>GH</given-names>
                    </name>
                    <name>
                      <surname>Nandy</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>McKenzie</surname>
                      <given-names>KM</given-names>
                    </name>
                  </person-group>
                  <article-title>Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data</article-title>
                  <source>Prostate</source>
                  <volume>76</volume>
                  <year>2016</year>
                  <fpage>48</fpage>
                  <lpage>57</lpage>
                  <pub-id pub-id-type="pmid">26419619</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0016">
                <label>16</label>
                <element-citation publication-type="journal" id="sbref0016">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hirata</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Bruchovsky</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Aihara</surname>
                      <given-names>K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer</article-title>
                  <source>J Theor Biol</source>
                  <volume>264</volume>
                  <year>2010</year>
                  <fpage>517</fpage>
                  <lpage>527</lpage>
                  <pub-id pub-id-type="pmid">20176032</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0017">
                <label>17</label>
                <element-citation publication-type="journal" id="sbref0017">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ideta</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Tanaka</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Takeuchi</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Aihara</surname>
                      <given-names>Z.</given-names>
                    </name>
                  </person-group>
                  <article-title>A mathematical model of intermittent androgen suppression for prostate cancer</article-title>
                  <source>J Nonlinear Sci</source>
                  <volume>18</volume>
                  <year>2008</year>
                  <fpage>593</fpage>
                  <lpage>614</lpage>
                </element-citation>
              </ref>
              <ref id="bib0018">
                <label>18</label>
                <element-citation publication-type="journal" id="sbref0018">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Portz</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Kuang</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Nagy</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy</article-title>
                  <source>AIP Advances</source>
                  <volume>2</volume>
                  <year>2012</year>
                  <fpage>011002-1</fpage>
                  <lpage>011002-14</lpage>
                </element-citation>
              </ref>
              <ref id="bib0019">
                <label>19</label>
                <element-citation publication-type="journal" id="sbref0019">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Strobl</surname>
                      <given-names>MAR</given-names>
                    </name>
                    <name>
                      <surname>West</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Viossat</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Damaghi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Robertson-Tessi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>JS</given-names>
                    </name>
                  </person-group>
                  <article-title>Turnover modulates the need for a cost of resistance in adaptive therapy</article-title>
                  <source>Cancer Res</source>
                  <year>2020</year>
                  <fpage>1135</fpage>
                  <lpage>1147</lpage>
                  <pub-id pub-id-type="pmid">33172930</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0020">
                <label>20</label>
                <element-citation publication-type="journal" id="sbref0020">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brady</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Enderling</surname>
                      <given-names>H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Mathematical models of cancer: when to predict novel therapies, and when not to</article-title>
                  <source>Bull Math Biol</source>
                  <year>2019</year>
                  <fpage>3722</fpage>
                  <lpage>3731</lpage>
                  <pub-id pub-id-type="pmid">31338741</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0021">
                <label>21</label>
                <element-citation publication-type="journal" id="sbref0021">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Azad</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Volik</surname>
                      <given-names>SV</given-names>
                    </name>
                    <name>
                      <surname>Wyatt</surname>
                      <given-names>AW</given-names>
                    </name>
                    <name>
                      <surname>Haegert</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Le Bihan</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Bell</surname>
                      <given-names>RH</given-names>
                    </name>
                  </person-group>
                  <article-title>Androgen receptor gene aberrations in circulating cell-free dna: biomarkers of therapeutic resistance in castration-resistant prostate cancer</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>21</volume>
                  <year>2015</year>
                  <fpage>2315</fpage>
                  <lpage>2324</lpage>
                  <pub-id pub-id-type="pmid">25712683</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0022">
                <label>22</label>
                <element-citation publication-type="journal" id="sbref0022">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kohli</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tan</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Zheng</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Montesinos</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Wong</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer</article-title>
                  <source>EBioMedicine</source>
                  <volume>54</volume>
                  <year>2020</year>
                  <object-id pub-id-type="publisher-id">102728</object-id>
                </element-citation>
              </ref>
              <ref id="bib0023">
                <label>23</label>
                <element-citation publication-type="journal" id="sbref0023">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sumiyoshi</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Mizuno</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Yamasaki</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Miyazaki</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Makino</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Okasho</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer</article-title>
                  <source>Sci Rep</source>
                  <volume>9</volume>
                  <year>2019</year>
                  <fpage>4030</fpage>
                  <pub-id pub-id-type="pmid">30858508</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0024">
                <label>24</label>
                <element-citation publication-type="journal" id="sbref0024">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wyatt</surname>
                      <given-names>AW</given-names>
                    </name>
                    <name>
                      <surname>Azad</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Volik</surname>
                      <given-names>SV</given-names>
                    </name>
                    <name>
                      <surname>Annala</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Beja</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>McConeghy</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer</article-title>
                  <source>JAMA Oncol</source>
                  <volume>2</volume>
                  <year>2016</year>
                  <fpage>1598</fpage>
                  <lpage>1606</lpage>
                  <pub-id pub-id-type="pmid">27148695</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0025">
                <label>25</label>
                <element-citation publication-type="journal" id="sbref0025">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scher</surname>
                      <given-names>HI</given-names>
                    </name>
                    <name>
                      <surname>Morris</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Basch</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Heller</surname>
                      <given-names>G.</given-names>
                    </name>
                  </person-group>
                  <article-title>End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice</article-title>
                  <source>J Clin Oncol</source>
                  <volume>29</volume>
                  <year>2011</year>
                  <fpage>3695</fpage>
                  <lpage>3704</lpage>
                  <pub-id pub-id-type="pmid">21859988</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0026">
                <label>26</label>
                <element-citation publication-type="journal" id="sbref0026">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Matsu-Ura</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Dovzhenok</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Aihara</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Rood</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Le</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Ren</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Intercellular coupling of the cell cycle and circadian clock in adult stem cell culture</article-title>
                  <source>Mol Cell</source>
                  <volume>64</volume>
                  <year>2016</year>
                  <fpage>900</fpage>
                  <lpage>912</lpage>
                  <pub-id pub-id-type="pmid">27867006</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0027">
                <label>27</label>
                <element-citation publication-type="journal" id="sbref0027">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Collins</surname>
                      <given-names>GS</given-names>
                    </name>
                    <name>
                      <surname>Reitsma</surname>
                      <given-names>JB</given-names>
                    </name>
                    <name>
                      <surname>Altman</surname>
                      <given-names>DG</given-names>
                    </name>
                    <name>
                      <surname>Moons</surname>
                      <given-names>KG.</given-names>
                    </name>
                  </person-group>
                  <article-title>Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the tripod statement</article-title>
                  <source>ann intern med</source>
                  <volume>162</volume>
                  <year>2015</year>
                  <fpage>55</fpage>
                  <lpage>63</lpage>
                  <pub-id pub-id-type="pmid">25560714</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0028">
                <label>28</label>
                <element-citation publication-type="journal" id="sbref0028">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Thomsen</surname>
                      <given-names>FB</given-names>
                    </name>
                    <name>
                      <surname>Westerberg</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Garmo</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Robinson</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Holmberg</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Olmert</surname>
                      <given-names>HD</given-names>
                    </name>
                  </person-group>
                  <article-title>Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study</article-title>
                  <source>PLoS One</source>
                  <volume>15</volume>
                  <year>2020</year>
                  <object-id pub-id-type="publisher-id">e0228447</object-id>
                </element-citation>
              </ref>
              <ref id="bib0029">
                <label>29</label>
                <element-citation publication-type="journal" id="sbref0029">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gravis</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Boher</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Joly</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Soulie</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Albiges</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Priou</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>Androgen Deprivation Therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial</article-title>
                  <source>Eur Urol</source>
                  <volume>70</volume>
                  <year>2016</year>
                  <fpage>256</fpage>
                  <lpage>262</lpage>
                  <pub-id pub-id-type="pmid">26610858</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0030">
                <label>30</label>
                <element-citation publication-type="journal" id="sbref0030">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sweeney</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>YH</given-names>
                    </name>
                    <name>
                      <surname>Carducci</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Jarrard</surname>
                      <given-names>DF</given-names>
                    </name>
                    <name>
                      <surname>Eisenberger</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Chemohormonal therapy in metastatic hormone-sensitive prostate cancer</article-title>
                  <source>N Engl J Med</source>
                  <volume>373</volume>
                  <year>2015</year>
                  <fpage>737</fpage>
                  <lpage>746</lpage>
                  <pub-id pub-id-type="pmid">26244877</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0031">
                <label>31</label>
                <element-citation publication-type="journal" id="sbref0031">
                  <person-group person-group-type="author">
                    <name>
                      <surname>James</surname>
                      <given-names>ND</given-names>
                    </name>
                    <name>
                      <surname>Sydes</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Clarke</surname>
                      <given-names>NW</given-names>
                    </name>
                    <name>
                      <surname>Mason</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Dearnaley</surname>
                      <given-names>DP</given-names>
                    </name>
                    <name>
                      <surname>Spears</surname>
                      <given-names>MR</given-names>
                    </name>
                  </person-group>
                  <article-title>Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial</article-title>
                  <source>Lancet</source>
                  <volume>387</volume>
                  <year>2016</year>
                  <fpage>1163</fpage>
                  <lpage>1177</lpage>
                  <pub-id pub-id-type="pmid">26719232</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0032">
                <label>32</label>
                <element-citation publication-type="journal" id="sbref0032">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bahl</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Oudard</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Tombal</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Ozgüroglu</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Hansen</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kocak</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial</article-title>
                  <source>Ann Oncol</source>
                  <volume>24</volume>
                  <year>2013</year>
                  <fpage>2402</fpage>
                  <lpage>2408</lpage>
                  <pub-id pub-id-type="pmid">23723295</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0033">
                <label>33</label>
                <element-citation publication-type="journal" id="sbref0033">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jaworska</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Szliszka</surname>
                      <given-names>E.</given-names>
                    </name>
                  </person-group>
                  <article-title>Targeting apoptotic activity against prostate cancer stem cells</article-title>
                  <source>Int J Mol Sci</source>
                  <volume>18</volume>
                  <year>2017</year>
                  <fpage>E1648</fpage>
                  <pub-id pub-id-type="pmid">28758908</pub-id>
                </element-citation>
              </ref>
              <ref id="bib0034">
                <label>34</label>
                <element-citation publication-type="journal" id="sbref0034">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Saeki</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Gu</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Yoshida</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>X.</given-names>
                    </name>
                  </person-group>
                  <article-title>Prostate stem cell antigen: a Jekyll and Hyde molecule?</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>16</volume>
                  <year>2010</year>
                  <fpage>3533</fpage>
                  <lpage>3538</lpage>
                  <pub-id pub-id-type="pmid">20501618</pub-id>
                </element-citation>
              </ref>
            </ref-list>
            <fn-group>
              <fn id="d34e182">
                <p id="notep0001">✩Conflict of Interest: The authors declare no potential conflicts of interest.</p>
              </fn>
            </fn-group>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
